Human Insulin Drugs and Delivery Devices

Human Insulin Drugs and Delivery Devices Market Outlook

The global Human Insulin Drugs and Delivery Devices market is projected to reach approximately USD 50 billion by 2035, growing at a compound annual growth rate (CAGR) of about 9.2% during the forecast period. This growth is largely driven by the increasing prevalence of diabetes coupled with the rising awareness about insulin delivery devices among patients. Furthermore, the growing geriatric population who are more susceptible to diabetes-related complications is anticipated to contribute significantly to the market expansion. Innovations in insulin formulations and delivery methods, such as smart insulin pens and automated insulin delivery systems, are expected to enhance patient compliance and effectiveness, thus propelling market growth. Additionally, advancements in technology and healthcare infrastructure are facilitating better access to diabetes management solutions globally, making insulin drugs and delivery devices more available to a wider population.

Growth Factor of the Market

The Human Insulin Drugs and Delivery Devices market is experiencing notable growth due to several compelling factors. The rising incidence of diabetes, particularly Type 2 diabetes, is a major driver, as more individuals are diagnosed and require insulin for management. Lifestyle changes, including increased sedentary behavior and unhealthy dietary habits, have contributed to this rise, necessitating effective treatment options. Additionally, technological advancements in insulin delivery devices have improved the efficiency and convenience of administering insulin, making it easier for patients to manage their condition. Furthermore, government initiatives aimed at enhancing diabetes care and support systems play a crucial role in market expansion. The increased focus on personalized medicine and targeted therapies also presents opportunities for innovation in insulin drug formulations, driving further growth in this dynamic sector.

Key Highlights of the Market

• The market is projected to grow at a CAGR of 9.2% from 2025 to 2035.
• Technological advancements in insulin delivery systems are enhancing patient adherence.
• Type 2 diabetes accounts for a significant share of the overall insulin demand.
• North America leads the market due to high diabetes prevalence and advanced healthcare systems.
• Online pharmacies are emerging as a key distribution channel, expanding patient access to insulin products.

By Product Type

Insulin Pens:

Insulin pens are one of the most popular delivery devices among diabetic patients due to their ease of use and convenience. These pre-filled or refillable devices enable users to administer insulin with precision, ensuring accurate dosage. The design of insulin pens often incorporates features such as dose memory and removable needles, which enhance usability and minimize discomfort for patients. The increasing adoption of insulin pens is also driven by manufacturers’ efforts to innovate with smart technologies, allowing connectivity to mobile apps for better tracking of insulin administration. As a result, insulin pens are expected to dominate the product type segment of the market, providing a user-friendly alternative to traditional syringes.

Insulin Pumps:

Insulin pumps are another significant product in the insulin delivery devices market, providing a continuous supply of insulin to patients through subcutaneous infusion. This technology allows for better blood glucose control compared to multiple daily injections, making it a preferable option for many Type 1 diabetes patients. With the rapid advancements in technology, modern insulin pumps now come equipped with features such as continuous glucose monitoring, automated insulin delivery, and smartphone connectivity, enhancing patient monitoring and management. The convenience and flexibility offered by insulin pumps, especially for those with hectic lifestyles, are driving their increasing adoption across various demographics.

Insulin Syringes:

Insulin syringes have been one of the traditional methods of insulin delivery and continue to be widely used, particularly among patients who prefer a straightforward approach. Despite the rise of more advanced devices like insulin pens and pumps, syringes remain a staple in diabetes management due to their affordability and availability. These syringes come in various sizes and are designed for single-use, which minimizes the risk of contamination. In developing regions where advanced devices may not be readily accessible, insulin syringes play a crucial role in diabetes care. Moreover, the continuous efforts to improve syringe design for better ergonomics and reduced pain are expected to keep this product relevant in the market.

Insulin Jet Injectors:

Insulin jet injectors are non-needle insulin delivery devices that utilize a high-pressure jet to deliver insulin into the subcutaneous tissue. This method appeals to patients who have a fear of needles or those who experience discomfort with traditional delivery methods. Jet injectors provide a rapid and almost painless delivery, which is an attractive feature for many users. However, the adoption of this technology has been moderate due to the higher costs associated with jet injectors compared to syringes and pens. Despite this, ongoing innovations and the push for needle-free solutions are anticipated to revive interest in jet injectors, particularly among new patients.

Insulin Inhalers:

Insulin inhalers represent a novel approach to insulin delivery, allowing patients to inhale powdered insulin through the lungs. This method offers a non-invasive alternative that can be more convenient and less intimidating for some individuals. Inhaled insulin is rapidly absorbed into the bloodstream, providing quick control over blood glucose levels after meals. However, the uptake of inhalers has been limited due to concerns about lung health and the specific patient populations that can benefit from this method. Nonetheless, ongoing research into the efficacy and safety of inhaled insulin continues to provide insights that may improve market acceptance and utilization in the future.

By Application

Type 1 Diabetes:

Type 1 diabetes is a chronic condition primarily affecting children and young adults, characterized by the autoimmune destruction of insulin-producing beta cells in the pancreas. Patients with Type 1 diabetes rely entirely on external insulin for survival, making the Human Insulin Drugs and Delivery Devices market particularly critical for this demographic. The increasing incidence of Type 1 diabetes globally is leading to a heightened demand for effective insulin delivery solutions. Innovations in insulin formulations, including faster-acting insulins and advanced technology in insulin pumps, are aimed at improving glycemic control and quality of life for these patients. As awareness of Type 1 diabetes grows, along with a focus on personalized treatment approaches, this segment is expected to drive substantial growth in the market.

Type 2 Diabetes:

Type 2 diabetes is the most common form of diabetes, often linked to lifestyle factors and obesity, and typically develops in adults. It involves insulin resistance, where the body does not use insulin effectively. This segment constitutes the largest share of the insulin delivery market, as many individuals with Type 2 diabetes may eventually require insulin therapy to manage their condition. With the rising obesity rates and sedentary lifestyles contributing to the increasing prevalence of Type 2 diabetes, there is a growing need for convenient and effective insulin delivery devices. The market is witnessing a trend toward integrating digital health technologies, such as mobile applications and remote monitoring, to support patients in managing their diabetes more effectively.

Gestational Diabetes:

Gestational diabetes occurs during pregnancy and usually resolves after childbirth, but it poses significant health risks for both mothers and infants. The management of gestational diabetes often involves a combination of dietary changes and insulin therapy when necessary. As awareness of gestational diabetes rises, healthcare professionals are increasingly recommending monitoring and, when required, the use of insulin delivery devices for effective control. The need for safe and effective solutions tailored to pregnant women and their unique physiological changes presents a growing opportunity for the insulin delivery market. These devices must be designed with the utmost consideration for safety and ease of use to accommodate the concerns of expectant mothers.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of Human Insulin Drugs and Delivery Devices, serving as a primary source for patients admitted to healthcare facilities. These pharmacies provide specialized services, including the preparation of customized insulin regimens for patients who may have unique needs. The presence of healthcare professionals allows for detailed consultations, ensuring patients receive comprehensive care and education about their insulin therapies. As hospitals increasingly focus on providing integrated diabetes care, the demand for insulin products through hospital pharmacies is expected to grow. Additionally, partnerships between pharmaceutical companies and hospitals are further enhancing the accessibility of insulin therapies within hospital settings.

Retail Pharmacies:

Retail pharmacies are a significant distribution channel for Human Insulin Drugs and Delivery Devices, providing easy access to a wide array of insulin products for patients managing diabetes. With the increasing prevalence of diabetes, retail pharmacies have adapted by stocking a diverse range of insulin therapies and delivery devices to meet patient needs. This sector is characterized by high competition and price sensitivity, compelling pharmacies to implement loyalty programs and promotional offers to attract and retain customers. Moreover, pharmacists play an essential role in patient education, helping individuals understand the proper use of insulin products, which enhances adherence to prescribed therapies. With the growing trend of "pharmacy as a health destination," retail pharmacies are poised to continue expanding their offerings in diabetes care.

Online Pharmacies:

Online pharmacies have emerged as a vital distribution channel, offering convenience and accessibility for patients seeking insulin drugs and delivery devices. The rise of e-commerce has transformed the way consumers access healthcare products, allowing patients to order insulin therapies from the comfort of their homes. This is especially beneficial for individuals who may have mobility issues or those living in remote areas with limited access to local pharmacies. Online pharmacies often provide competitive pricing and exclusive promotions, which can be appealing to cost-conscious consumers. Furthermore, the integration of telehealth services and personalized care pathways through online platforms enhances the overall patient experience, making this channel an integral component of the Human Insulin Drugs and Delivery Devices market.

By Ingredient Type

Rapid-Acting Insulin:

Rapid-acting insulin is designed to be absorbed quickly by the body, providing immediate glucose control after meals. This type of insulin is particularly beneficial for patients who require flexibility in their meal timing and is often used in conjunction with a longer-acting insulin to create a comprehensive insulin regimen. The convenience and effectiveness of rapid-acting insulin make it increasingly popular among both Type 1 and Type 2 diabetes patients. The advancements in formulation technology have further enhanced the efficacy and onset of rapid-acting insulins, driving their adoption in the market. Given the modern lifestyle demands and the critical need for immediate blood sugar management, the demand for rapid-acting insulin is expected to continue to rise.

Short-Acting Insulin:

Short-acting insulin provides a sustained release of insulin, allowing for effective management of blood glucose levels around meal times. This type of insulin is typically administered 30 to 60 minutes before eating, allowing it to be absorbed and begin lowering blood sugar levels in a timely manner. While newer formulations such as rapid-acting insulins have gained prominence, short-acting insulins remain a key choice for many patients due to their reliability and effectiveness. Healthcare providers often recommend short-acting insulin for patients who may not require continuous infusion or those who prefer a more traditional insulin regimen. This segment remains relevant in the Human Insulin Drugs and Delivery Devices market, particularly among long-standing diabetes management practices.

Intermediate-Acting Insulin:

Intermediate-acting insulin provides a balance of onset and duration, making it suitable for patients who require insulin coverage throughout the day and night. This type of insulin is often utilized in conjunction with short-acting or rapid-acting insulins to create a comprehensive insulin therapy plan. For many patients, intermediate-acting insulin serves as a foundational component of their diabetes management, particularly for those who may not have access to advanced delivery devices. The affordability and availability of intermediate-acting insulin ensure its continued relevance within the market, especially in regions with limited healthcare resources. As more patients gain access to diabetes care, the demand for this type of insulin is expected to remain stable.

Long-Acting Insulin:

Long-acting insulin provides a steady release of insulin over an extended period, allowing for consistent blood glucose control throughout the day and night. This type of insulin is particularly advantageous for patients who require a baseline level of insulin to manage their condition effectively. Long-acting insulin formulations have undergone significant advancements, with the introduction of ultralong-acting insulins that can last up to 36 hours, providing increased flexibility in dosing schedules. The growing awareness among healthcare professionals and patients about the benefits of long-acting insulin in achieving optimal glycemic control is driving its demand. Furthermore, the patient-friendly dosing schedules and reduced frequency of administration associated with long-acting insulins are enhancing their appeal in the market.

Premixed Insulin:

Premixed insulin combines both rapid-acting and intermediate-acting insulin in a single injection, providing convenience for patients who prefer a simplified insulin regimen. This formulation is particularly appealing to those who may struggle with multiple daily injections or have difficulty managing a complex dosing schedule. Premixed insulin allows for both mealtime coverage and basal insulin needs to be addressed simultaneously, making it a practical option for many individuals with diabetes. Despite the increasing popularity of individualized dosing regimens with rapid and long-acting insulins, premixed formulations continue to hold a significant share of the market due to their ease of use and effectiveness. The continued innovation in premixed insulin formulations is expected to sustain its demand among patients seeking streamlined diabetes management solutions.

By Region

The North American region dominates the Human Insulin Drugs and Delivery Devices market, accounting for a significant share of the global market. The high prevalence of diabetes, particularly Type 2 diabetes, along with advanced healthcare infrastructure and strong distribution channels, contributes to this dominance. The United States, in particular, exhibits a high demand for innovative insulin delivery devices, with a growing focus on personalized diabetes management solutions. The market in North America is projected to grow at a CAGR of approximately 8.5% during the forecast period, driven by a commitment to improving diabetes care and management through technological advancements. Additionally, increasing awareness and accessibility to healthcare services are likely to bolster insulin therapy penetration within this region.

In Europe, the Human Insulin Drugs and Delivery Devices market is also witnessing robust growth, supported by rising diabetes prevalence and supportive government initiatives aimed at improving diabetes care. The European region accounts for a substantial share of the market, with countries such as Germany, France, and the United Kingdom leading in demand for insulin products and delivery devices. The market growth in Europe is bolstered by a strong emphasis on research and development in diabetes management, alongside the establishment of comprehensive healthcare systems that facilitate patient access to essential treatments. The CAGR for the European market is forecasted to be around 7.8%, indicating a steady increase in insulin therapy utilization and advancements in delivery technologies.

Opportunities

The Human Insulin Drugs and Delivery Devices market presents numerous opportunities driven by technological advancements and growing awareness surrounding diabetes management. One of the most significant opportunities lies in the integration of digital health technologies with insulin delivery systems. With the rise of mobile health applications and continuous glucose monitoring devices, healthcare providers can offer personalized treatment plans that enhance patient engagement and adherence. This technology-driven approach not only improves diabetes management but also empowers patients to take control of their health, thereby increasing the demand for innovative insulin delivery solutions. Moreover, the expansion of telemedicine services is creating new avenues for patient education and support, which can significantly boost the market for insulin drugs and delivery devices.

Another promising opportunity stems from the increasing focus on preventative healthcare and early diagnosis of diabetes. With growing initiatives aimed at raising awareness about the risk factors associated with diabetes, patients are seeking proactive measures to manage their health. This shift towards prevention is prompting healthcare providers and pharmaceutical companies to invest in research and development aimed at creating new insulin formulations and delivery devices that cater to the evolving needs of patients. Furthermore, the potential for collaborations between pharmaceutical companies and technology firms to develop smart insulin delivery systems could further transform the landscape of diabetes management, creating a competitive edge in the Human Insulin Drugs and Delivery Devices market.

Threats

Despite the promising prospects within the Human Insulin Drugs and Delivery Devices market, several threats could hinder growth. One significant concern is the rising cost of healthcare, which may limit access to insulin therapies for patients, particularly in emerging markets. The financial burden associated with diabetes management can discourage some individuals from seeking timely treatment or adhering to prescribed regimens. Additionally, the increasing prevalence of counterfeit and substandard insulin products, especially in developing regions, poses a significant threat to patient safety and overall market integrity. Regulatory challenges and stringent compliance requirements can further complicate the approval process for new insulin formulations and delivery systems, creating hurdles for companies aiming to innovate in this space.

Moreover, the competitive landscape of the insulin delivery market is intensifying, with numerous players vying for market share. The presence of established pharmaceutical companies with strong research and development capabilities creates a challenging environment for new entrants. Price wars and aggressive marketing strategies among competitors can lead to reduced profit margins and create instability in the market. Additionally, evolving patient preferences towards more advanced and user-friendly delivery systems may render traditional insulin delivery methods obsolete, posing a threat to companies that fail to adapt to changing consumer expectations. The combination of these factors underscores the importance of strategic planning and innovation to navigate the complexities of this dynamic market.

Competitor Outlook

• Sanofi
• Novartis
• Roche
• Abbott Laboratories
• Johnson & Johnson
• Merck & Co.
• Pfizer
• Eli Lilly and Company
• Boehringer Ingelheim
• Teva Pharmaceutical Industries
• Insulet Corporation
• Medtronic
• Dexcom
• Novo Nordisk

The competitive landscape of the Human Insulin Drugs and Delivery Devices market is characterized by a mix of established pharmaceutical companies and emerging players, all striving to capture market share through innovation and strategic partnerships. Leading companies such as Novo Nordisk and Sanofi dominate the market with their extensive portfolios of insulin products, ranging from traditional formulations to advanced delivery systems. These players are investing heavily in research and development to create next-generation insulin therapies that cater to evolving patient needs. Moreover, collaborations with technology firms are becoming increasingly common, enabling pharmaceutical companies to integrate digital health solutions into their product offerings, enhancing patient engagement and adherence to treatment regimens.

Insulet Corporation and Medtronic are notable players in the insulin pump segment, focusing on innovations that enhance the user experience and improve glycemic control. Their continuous efforts to introduce automated insulin delivery systems and integration with continuous glucose monitors position them as leaders within this niche of the market. Additionally, companies like Dexcom are making strides in developing advanced glucose monitoring technologies that complement insulin delivery devices, creating a holistic approach to diabetes management. This interconnectedness between monitoring and delivery systems is expected to become a significant trend in the future, further intensifying competition among major players.

Furthermore, the market is also witnessing the entry of smaller biotech firms that are focusing on niche segments and developing unique insulin formulations or delivery methods. These companies are often agile and capable of rapid innovation, allowing them to cater to specific patient needs more effectively. The competitive dynamics are thus shaped by a variety of factors, including product differentiation, pricing strategies, and the ability to leverage technological advancements. As the market continues to evolve, companies that prioritize patient-centric solutions and invest in innovative technologies will likely emerge as frontrunners in the Human Insulin Drugs and Delivery Devices market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Roche
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Dexcom
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Medtronic
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Merck & Co.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Novo Nordisk
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Johnson & Johnson
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Abbott Laboratories
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Insulet Corporation
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Boehringer Ingelheim
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Eli Lilly and Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceutical Industries
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Human Insulin Drugs and Delivery Devices Market, By Application
    • 6.1.1 Type 1 Diabetes
    • 6.1.2 Type 2 Diabetes
    • 6.1.3 Gestational Diabetes
  • 6.2 Human Insulin Drugs and Delivery Devices Market, By Product Type
    • 6.2.1 Insulin Pens
    • 6.2.2 Insulin Pumps
    • 6.2.3 Insulin Syringes
    • 6.2.4 Insulin Jet Injectors
    • 6.2.5 Insulin Inhalers
  • 6.3 Human Insulin Drugs and Delivery Devices Market, By Ingredient Type
    • 6.3.1 Rapid-Acting Insulin
    • 6.3.2 Short-Acting Insulin
    • 6.3.3 Intermediate-Acting Insulin
    • 6.3.4 Long-Acting Insulin
    • 6.3.5 Premixed Insulin
  • 6.4 Human Insulin Drugs and Delivery Devices Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Human Insulin Drugs and Delivery Devices Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Human Insulin Drugs and Delivery Devices market is categorized based on

By Product Type

• Insulin Pens
• Insulin Pumps
• Insulin Syringes
• Insulin Jet Injectors
• Insulin Inhalers

By Application

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Rapid-Acting Insulin
• Short-Acting Insulin
• Intermediate-Acting Insulin
• Long-Acting Insulin
• Premixed Insulin

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Sanofi
• Novartis
• Roche
• Abbott Laboratories
• Johnson & Johnson
• Merck & Co.
• Pfizer
• Eli Lilly and Company
• Boehringer Ingelheim
• Teva Pharmaceutical Industries
• Insulet Corporation
• Medtronic
• Dexcom
• Novo Nordisk